A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Trial Profile

A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2018

At a glance

  • Drugs Avelumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Ovarian cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms JAVELIN Ovarian 100
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 04 Apr 2017 Planned End Date changed from 6 Sep 2019 to 1 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top